Perrigo vitamin settlement
This article was originally published in The Tan Sheet
Executive Summary
Private labeler will record $7.8 mil. pre-tax gain in third quarter ending March 31 stemming from settlement with unidentified defendants in vitamin price-fixing litigation. "Effect on net income will be approximately $5 mil.," firm says in Feb. 1 SEC filing. Case against remaining price-fixing defendants is proceeding, notes Allegan, Mich.-based firm, which previously reported vitamin litigation settlement payments of $995,000 and $4.2 mil. for FY 2001 and 2000, respectively...
You may also be interested in...
Perrigo vitamin settlement
Private labeler will record $20.1 mil. pre-tax gain in fiscal fourth quarter ending June 30 stemming from settlements in vitamin price-fixing litigation. Settlement proceeds, which were received May 17, will boost net income by approximately $12.9 mil. Perrigo recorded $7.8 mil. pre-tax gain in Q3 following similar settlements (1"The Tan Sheet" Feb. 18, 2002, p. 14)...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.